HOGAN LOVELLS US LLP
J. Tom Boer (State Bar No. 199563)
tom.boer@hoganlovells.com
Maia H. Jorgensen (State Bar No. 344980)
maia.jorgensen@hoganlovells.com
4 Embarcadero Center, Suite 3500
San Francisco, California 94111
Telephone: (415) 374-2300
Facsimile: (415) 374-2499

Attorneys for Petitioner
B. BRAUN US PHARMACEUTICAL MANUFACTURING LLC

BEFORE THE HEARING BOARD OF THE SOUTH COAST AIR QUALITY MANAGEMENT DISTRICT

In the Matter of B. BRAUN US PHARMACEUTICAL MANUFACTURING LLC, Petitioner, v. SOUTH COAST AIR QUALITY MANAGEMENT DISTRICT, Respondent.	CASE NO. 4780-5 FACILITY ID NO. 117290 **DECLARATION OF TIM HELLEM IN SUPPORT OF B. BRAUN US PHARMACEUTICAL MANUFACTURING LLC'S PETITION FOR MODIFICATION / EXTENSION OF A FINAL COMPLIANCE DATE** **Date:** January 30, 2025 **Time:** 9:30 AM **Location:** 21865 Copley Drive Diamond Bar, CA 91765

I, Tim Hellem, declare:

1. This declaration is made, pursuant to Rule 4 of the SCAQMD Hearing Board Rules and Procedures, in support of B. Braun US Pharmaceutical Manufacturing LLC's ("Pharma" or the "Company") second Petition for Modification of an Existing Variance filed with the South Coast Air Quality Management District ("SCAQMD" or the "District") Hearing Board in Case No. 4870-5 on December 13, 2024.

2. I am the Head of Environmental, Health & Safety ("EHS") for the Pharma manufacturing facility located at 2525 McGaw Avenue in Irvine, California (the "Irvine Facility" or "Facility"). As stated in my December 7, 2023, declaration, filed as Petitioner's Exhibit No. 6, I have been the Head of EHS at the Irvine Facility since April of 2020.

3. As the Head of EHS at the Irvine Facility, I am responsible for, among other things, ensuring the Facility complies with all relevant EHS regulations and environmental permits, including Pharma's Title V Permit to Operate (the "Permit") as modified by the variance issued by the SCAQMD Hearing Board in connection with the Facility's two cogeneration turbines – Turbine No. 1 (D28) and Turbine No. 2 (D35) (collectively, the "Cogens" or "Turbines").

4. Pharma is in compliance with Condition Nos. 4 and 5 of the variance, which require the Company to maintain the existing Relative Accuracy Test Audits (RATAs) and service schedules for the Cogens. The 2024 RATA source test for Turbine No. 2 (D35) was performed in August of 2024 and the RATA source test for Turbine No. 1 (D28) was performed in December of 2024. The Cogens both received a full annual service in September of 2024.

5. During a further extension of the variance period, Pharma will continue to:

   a. operate the Cogens in compliance with all applicable SCAQMD Rules and the Permit, except for the NOx emissions standard subject to the variance;

   b. comply with all existing variance Conditions, as modified by this petition; and

   c. tune and ensure proper operation of the Cogens.

6. Upon information and belief, operation of the Cogens between January 1, 2024 (the start date of the variance) and the date of this declaration has not caused a nuisance due to any

discharge of air contaminants or other material resulting in injury, detriment, nuisance, or annoyance to any considerable number of persons or the public, or endangered the comfort, repose, health, or safety of any person or the public. Similarly, continued operation of the Cogens during an extended variance period is not expected to result in a violation of California Health and Safety Code Section 41700 (nuisance).

7. Pursuant to the Permit, Pharma continuously monitors emissions from the Turbines through the Facility's CEMS and will continue to do so during the variance period, as extended. Pharma will continue to report this data daily to SCAQMD via the RECLAIM WATERS system.

8. B. Braun will continue to comply with 4.5MW cap on Cogen usage, as prescribed by variance Condition No. 3, during the extended variance period.

I declare under penalty of perjury under the laws of the State of California that the foregoing is true and correct. Executed this 22nd day of January, 2025, at Irvine, California.

TIM HELLEM
Head of EHS
Pharma